RxDoctor Payments Data

Marc Nolan, MD

Cardiovascular Disease · New York, NYNPI 1144295312

Payments from drug & device makers

$2,065in general payments, 2019–2025

Across 52 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$1K
  • Pfizer$317
  • Novartis$188
  • Boehringer Ingelheim$183
  • Johnson & Johnson$129
  • Lilly USA, LLC$40
  • plus $136 from 5 others

What the payments were for

  • Food & beverage$99448%
  • Other$1,07152%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,065 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$532,768
Medicare patients
447
Services billed
4,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$193,674
XareltoRivaroxaban54$65,191
EntrestoSacubitril/Valsartan33$41,725
OzempicSemaglutide29$41,212
JardianceEmpagliflozin28$37,900
JanuviaSitagliptin Phosphate26$30,547
Repatha SureclickEvolocumab29$22,444
Repatha SyringeEvolocumab16$15,627
LokelmaSodium Zirconium Cyclosilicate13$6,344
Atorvastatin Calcium551$5,759
Breo ElliptaFluticasone/Vilanterol14$5,707
Losartan Potassium483$5,109
Metoprolol Succinate302$4,958
SynthroidLevothyroxine Sodium65$3,961
Ezetimibe139$3,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$317$193,674132 claims
Johnson & JohnsonXarelto$129$65,19154 claims
NovartisEntresto$188$41,72533 claims
Novo NordiskOzempic$18$41,21229 claims
Boehringer IngelheimJardiance$183$37,90028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →